Clinical Trials
14 trialsNCT07334119 2026-05-20
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Phase 1 Recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT04900818 2026-03-05
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
I-Mab Biopharma US Limited
Phase 1 Recruiting
NCT03785873 2026-02-13
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Completed
NCT04278144 2025-09-15
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT04057365 2025-08-13
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
Phase 2 Terminated
NCT03639935 2025-06-03
Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03447470 2025-01-29
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
Phase 1 Completed
NCT03695952 2025-01-28
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Asan Medical Center
Active not recruiting
NCT02866383 2023-09-22
CheckPAC
Herlev Hospital
Phase 2 Completed
NCT03101566 2022-10-28
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03768531 2020-04-13
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT03311789 2017-10-17
Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs
Chinese PLA General Hospital
Phase 1/2 Unknown